

QUEST DIAGNOSTICS INC  
Form 4  
December 22, 2011

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
HAGEMANN ROBERT

(Last) (First) (Middle)

C/O QUEST DIAGNOSTICS  
INCORPORATED, 3 GIRALDA  
FARMS

(Street)

MADISON, NJ 07940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
QUEST DIAGNOSTICS INC  
[DGX]

3. Date of Earliest Transaction  
(Month/Day/Year)  
12/21/2011

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
SVP & Chief Financial Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V   | Amount or Price   |  |                                   |
| Common Stock                    | 12/21/2011                           |  | M <sup>(3)</sup>               |   | 1,650 A \$ 35.5325  | D  |                                   |
| Common Stock                    | 12/21/2011                           |  | S <sup>(3)</sup>               |   | 1,650 D \$ 57.7367 <sup>(4)</sup>   | D  |                                   |
| Common Stock                    | 12/21/2011                           |  | M <sup>(3)</sup>               |   | 2,500 A \$ 48.74  | D  |                                   |
| Common Stock                    | 12/21/2011                           |  | S <sup>(3)</sup>               |   | 2,500 D \$ 57.762 <sup>(5)</sup>  | D  |                                   |
|                                 |                                      |  |                                |   |   |  | 142,175 <sup>(6)</sup>            |

Common Stock 1,767 <sup>(7)</sup> I SDCP

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.** SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock Options (Right to Buy)               | \$ 35.5325   | 12/21/2011                           |  | M <sup>(3)</sup>               | 1,650   | <sup>(1)</sup> 02/27/2012                                | Common Stock  | 1,650                         |
| Stock Options (Right to Buy)               | \$ 48.74   | 12/21/2011                           |  | M <sup>(3)</sup>               | 2,500   | <sup>(2)</sup> 02/22/2012                                | Common Stock  | 2,500                         |

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director 10% Owner Officer Other

HAGEMANN ROBERT  
C/O QUEST DIAGNOSTICS INCORPORATED  
3 GIRALDA FARMS  
MADISON, NJ 07940

SVP & Chief Financial Officer

## Signatures

/s/ William J. O'Shaughnessy, Jr., Attorney in Fact for Robert Hagemann

12/22/2011

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options vested in three installments on April 17, 2003, February 27, 2004 and February 27, 2005.

(2) The options vested in three annual installments on February 22, 2006, February 22, 2007 and February 22, 2008.

(3) This exercise and sale reported were effected pursuant to Rule 10b-5-1 sales plan adopted by the reporting person on February 7, 2011.

This transaction was executed in multiple trades at prices ranging from \$57.50 to \$57.90. The price reported above reflects the weighted  
(4) average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

This transaction was executed in multiple trades at prices ranging from \$57.50 to \$57.92. The price reported above reflects the weighted  
(5) average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

(6) This amount also includes exempt purchases made under the Company's stock purchase plan.

These underlying shares were acquired on a periodic basis by the trustee of the Company's Supplemental Deferred Compensation Plan.

(7) The information was obtained from the plan administrator as of a recent date. The number of shares is based on the account balance of the Company stock fund under the plan (which includes some money market instruments), divided by the market price of the Company's stock as of that date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.